Posted by Michael Wonder on 10 Aug 2024
Amneal receives US FDA approval for IPX203 for treatment of Parkinson’s disease to be launched as Crexont (carbidopa and levodopa) extended release capsules
7 August 2024 - Crexont commercial launch planned in September 2024.
Amneal Pharmaceuticals today announced that the US FDA has approved Crexont (carbidopa and levodopa) extended release capsules for the treatment of Parkinson’s disease.
